Use of rituximab to decrease panel-reactive antibodies

被引：41

作者：

Balfour, IC

Fiore, A

Graff, RJ

Knutsen, AP

机构：

[1] St Louis Univ, Hlth Sci Ctr, Dept Pediat, Div Cardiol, St Louis, MO 63104 USA

[2] St Louis Univ, Hlth Sci Ctr, Div Cardiothorac Surg, Dept Surg,Histocompatibil & Immunogenet Lab, St Louis, MO 63104 USA

[3] St Louis Univ, Hlth Sci Ctr, Div Allergy Immunol, Dept Pediat, St Louis, MO 63104 USA

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2005年 / 24卷 / 05期

关键词：

D O I：

10.1016/j.healun.2004.01.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with pre-formed antibodies may be at increased risk of rejection after organ transplantation. In this report, we describe the use of rituximab to decrease the percentage of pre-formed antibodies in a pediatric heart transplant recipient. Copyright (c) 2005 by the International Society for Heart and Lung Transplantation.

引用

收藏

页码：628 / 630

页数：3

相关论文

共 7 条

[1] Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: A case report [J].

Aranda, JM ;

Scornik, JC ;

Normann, SJ ;

Lottenberg, R ;

Schofield, RS ;

Pauly, DF ;

Miles, M ;

Hill, JA ;

Sleasman, JW ;

Skoda-Smith, S .

TRANSPLANTATION, 2002, 73 (06) :907-910

[2] SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIG) - A POTENTIAL TOOL FOR TRANSPLANTATION OF IMMUNIZED PATIENTS [J].

GLOTZ, D ;

HAYMANN, JP ;

SANSONETTI, N ;

FRANCOIS, A ;

MENOYOCALONGE, V ;

BARIETY, J ;

DRUET, P .

TRANSPLANTATION, 1993, 56 (02) :335-337

[3]

GOERGE JF, 1995, J HEART LUNG TRANSPL, V14, P856

[4] Mycophenolate mofetil in renal allograft recipients - A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection [J].

Halloran, P ;

Mathew, T ;

Tomlanovich, S ;

Groth, C ;

Hooftman, L ;

Barker, C .

TRANSPLANTATION, 1997, 63 (01) :39-47

[5]

REFF ME, 1994, BLOOD, V83, P435

[6] Suppression of Panel-Reactive Antibodies by treatment with mycophenolate mofetil [J].

Schmid, C ;

Garritsen, HSP ;

Kelsch, R ;

Cassens, U ;

Baba, HA ;

Sibrowski, W ;

Scheld, HH .

THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (03) :161-162

[7] HISTOCOMPATIBILITY AND OTHER RISK-FACTORS FOR HISTOLOGICAL REJECTION OF HUMAN CARDIAC ALLOGRAFTS DURING THE 1ST 3 MONTHS FOLLOWING TRANSPLANTATION [J].

ZERBE, TR ;

ARENA, VC ;

KORMOS, RL ;

GRIFFITH, BP ;

HARDESTY, RL ;

DUQUESNOY, RJ .

TRANSPLANTATION, 1991, 52 (03) :485-490